Kairos Pharma Files 8-K Report
Ticker: KAPA · Form: 8-K · Filed: Feb 26, 2025 · CIK: 1962011
Sentiment: neutral
Topics: 8-K, regulatory-filing
TL;DR
Kairos Pharma filed an 8-K, likely with updates for investors.
AI Summary
On February 26, 2025, Kairos Pharma, LTD. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits" without detailing specific transactions or financial figures within the provided text. The company is incorporated in Delaware and its principal executive offices are located in Los Angeles, California.
Why It Matters
This filing indicates that Kairos Pharma, LTD. has submitted a current report to the SEC, which may contain material updates for investors regarding the company's operations or financial status.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report without specific negative or positive disclosures in the provided text, indicating a routine regulatory submission.
Key Players & Entities
- Kairos Pharma, LTD. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- 2355 Westwood Blvd. , #139 Los Angeles CA 90064 (address) — Principal executive offices
- February 26, 2025 (date) — Date of earliest event reported
FAQ
What specific "Other Events" are being reported by Kairos Pharma, LTD. in this 8-K filing?
The provided text for the 8-K filing does not specify the details of the "Other Events" beyond listing it as an item of information.
What "Financial Statements and Exhibits" are included with this 8-K filing?
The provided text for the 8-K filing lists "Financial Statements and Exhibits" as an item of information but does not detail their content.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on February 26, 2025.
What is the principal executive office address for Kairos Pharma, LTD.?
The principal executive office address for Kairos Pharma, LTD. is 2355 Westwood Blvd. , #139 Los Angeles CA 90064.
Under which section of the Securities Exchange Act of 1934 is this 8-K report filed?
This 8-K report is filed pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 26, 2025 regarding Kairos Pharma, LTD. (KAPA).